Cargando…
Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients
Immunocompromised patients have a high risk of death from SARS-CoV-2 infection. Vaccination with an mRNA vaccine may protect these patients against severe COVID-19. Several studies have evaluated the impact of immune-suppressive drug regimens on cellular and humoral responses to SARS-CoV-2 variants...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441691/ https://www.ncbi.nlm.nih.gov/pubmed/36072955 http://dx.doi.org/10.3389/fmed.2022.978764 |
_version_ | 1784782638695841792 |
---|---|
author | Wiedemann, Aurélie Pellaton, Céline Dekeyser, Manon Guillaumat, Lydia Déchenaud, Marie Krief, Corinne Lacabaratz, Christine Grimbert, Philippe Pantaleo, Giuseppe Lévy, Yves Durrbach, Antoine |
author_facet | Wiedemann, Aurélie Pellaton, Céline Dekeyser, Manon Guillaumat, Lydia Déchenaud, Marie Krief, Corinne Lacabaratz, Christine Grimbert, Philippe Pantaleo, Giuseppe Lévy, Yves Durrbach, Antoine |
author_sort | Wiedemann, Aurélie |
collection | PubMed |
description | Immunocompromised patients have a high risk of death from SARS-CoV-2 infection. Vaccination with an mRNA vaccine may protect these patients against severe COVID-19. Several studies have evaluated the impact of immune-suppressive drug regimens on cellular and humoral responses to SARS-CoV-2 variants of concern in this context. We performed a prospective longitudinal study assessing specific humoral (binding and neutralizing antibodies against spike (S) and T-lymphocyte (cytokine secretion and polyfunctionality) immune responses to anti-COVID-19 vaccination with at least two doses of BNT162b2 mRNA vaccine in stable kidney transplant recipients (KTR) on calcineurin inhibitor (CNI)- or belatacept-based treatment regimens. Fifty-two KTR−31 receiving CNI and 21 receiving belatacept—were enrolled in this study. After two doses of vaccine, 46.9% of patients developed anti-S IgG. Anti-spike IgG antibodies were produced in only 21.4% of the patients in the belatacept group, vs. 83.3% of those in the CNI group. The Beta and Delta variants and, more importantly, the Omicron variant, were less well neutralized than the Wuhan strain. T-cell functions were also much weaker in the belatacept group than in the CNI group. Renal transplant patients have an impaired humoral response to BNT162b2 vaccination. Belatacept-based regimens severely weaken both humoral and cellular vaccine responses. Clinically, careful evaluations of at least binding IgG responses, and prophylactic or post-exposure strategies are strongly recommended for transplant recipients on belatacept-based regimens. |
format | Online Article Text |
id | pubmed-9441691 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94416912022-09-06 Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients Wiedemann, Aurélie Pellaton, Céline Dekeyser, Manon Guillaumat, Lydia Déchenaud, Marie Krief, Corinne Lacabaratz, Christine Grimbert, Philippe Pantaleo, Giuseppe Lévy, Yves Durrbach, Antoine Front Med (Lausanne) Medicine Immunocompromised patients have a high risk of death from SARS-CoV-2 infection. Vaccination with an mRNA vaccine may protect these patients against severe COVID-19. Several studies have evaluated the impact of immune-suppressive drug regimens on cellular and humoral responses to SARS-CoV-2 variants of concern in this context. We performed a prospective longitudinal study assessing specific humoral (binding and neutralizing antibodies against spike (S) and T-lymphocyte (cytokine secretion and polyfunctionality) immune responses to anti-COVID-19 vaccination with at least two doses of BNT162b2 mRNA vaccine in stable kidney transplant recipients (KTR) on calcineurin inhibitor (CNI)- or belatacept-based treatment regimens. Fifty-two KTR−31 receiving CNI and 21 receiving belatacept—were enrolled in this study. After two doses of vaccine, 46.9% of patients developed anti-S IgG. Anti-spike IgG antibodies were produced in only 21.4% of the patients in the belatacept group, vs. 83.3% of those in the CNI group. The Beta and Delta variants and, more importantly, the Omicron variant, were less well neutralized than the Wuhan strain. T-cell functions were also much weaker in the belatacept group than in the CNI group. Renal transplant patients have an impaired humoral response to BNT162b2 vaccination. Belatacept-based regimens severely weaken both humoral and cellular vaccine responses. Clinically, careful evaluations of at least binding IgG responses, and prophylactic or post-exposure strategies are strongly recommended for transplant recipients on belatacept-based regimens. Frontiers Media S.A. 2022-08-22 /pmc/articles/PMC9441691/ /pubmed/36072955 http://dx.doi.org/10.3389/fmed.2022.978764 Text en Copyright © 2022 Wiedemann, Pellaton, Dekeyser, Guillaumat, Déchenaud, Krief, Lacabaratz, Grimbert, Pantaleo, Lévy and Durrbach. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Wiedemann, Aurélie Pellaton, Céline Dekeyser, Manon Guillaumat, Lydia Déchenaud, Marie Krief, Corinne Lacabaratz, Christine Grimbert, Philippe Pantaleo, Giuseppe Lévy, Yves Durrbach, Antoine Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients |
title | Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients |
title_full | Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients |
title_fullStr | Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients |
title_full_unstemmed | Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients |
title_short | Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients |
title_sort | longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to covid-19 vaccination in kidney transplant recipients |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441691/ https://www.ncbi.nlm.nih.gov/pubmed/36072955 http://dx.doi.org/10.3389/fmed.2022.978764 |
work_keys_str_mv | AT wiedemannaurelie longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients AT pellatonceline longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients AT dekeysermanon longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients AT guillaumatlydia longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients AT dechenaudmarie longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients AT kriefcorinne longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients AT lacabaratzchristine longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients AT grimbertphilippe longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients AT pantaleogiuseppe longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients AT levyyves longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients AT durrbachantoine longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients |